Abstract | BACKGROUND AND AIMS: METHODS: Seventy eight consecutive CHB patients from five European centers were included. All started a TDF + FTC combination between October 2005 and March 2010. Virological, biochemical, and clinical data were recorded during follow-up. Tolerance was also monitored. Patients were classified into either treatment simplification (TS), where efficacy of the previous treatment was obtained at TDF + FTC initiation, and treatment intensification (TI), where the previous line of therapy had failed. RESULTS: TDF + FTC was given as a TI to 54 patients (69%) and as a TS to 24 (31%). Among patients with TI, 83% were males. The median baseline HBV- DNA was 4.4 log10 IU/mL, and median alanine-transaminase (ALT) was 1.10 × ULN. Sixty percent were HBeAg positive, 47% had significant fibrosis (≥ F3 Metavir equivalent), and 29% had confirmed cirrhosis. Median treatment duration was 76 weeks (interquartile range 60-116). Kaplan-Meier analysis showed that, 48 weeks after TI, the probability of being HBV- DNA becoming undetectable was 76%, and reached 94% at week 96. No viral breakthrough occurred. Patients with TS (87% males, median baseline HBV- DNA 1.1 log10 IU/mL, median ALT 0.79 × ULN, 33% HBeAg positive, 61% with significant fibrosis) were treated for a median duration of 76 weeks. In this subgroup, all patients but one remained HBV- DNA undetectable and no ALT flare-up occurred during follow-up. Creatinine levels did not show kidney-function deterioration in either group of patients. CONCLUSIONS: After a median follow-up of > 76 weeks, the TDF + FTC combination showed encouraging antiviral efficacy and a good safety profile in all patients with CHB. TDF + FTC may represent an interesting clinical option to simplify therapy and increase the barrier to resistance, which should be assessed in the long term.
|
Authors | Si-Nafa Si-Ahmed, Pierre Pradat, Roeland Zoutendijk, Maria Buti, Vincent Mallet, Claire Cruiziat, Katja Deterding, Jérôme Dumortier, François Bailly, Rafael Esteban, Heiner Wedemeyer, Harry L Janssen, Fabien Zoulim |
Journal | Antiviral research
(Antiviral Res)
Vol. 92
Issue 1
Pg. 90-5
(Oct 2011)
ISSN: 1872-9096 [Electronic] Netherlands |
PMID | 21767570
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier B.V. All rights reserved. |
Chemical References |
- Antiviral Agents
- Organophosphonates
- Deoxycytidine
- Tenofovir
- Emtricitabine
- Adenine
|
Topics |
- Adenine
(administration & dosage, adverse effects, analogs & derivatives)
- Adult
- Aged
- Antiviral Agents
(administration & dosage)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Drug Therapy, Combination
- Emtricitabine
- Europe
- Follow-Up Studies
- Hepatitis B, Chronic
(drug therapy)
- Humans
- Male
- Middle Aged
- Organophosphonates
(administration & dosage, adverse effects)
- Tenofovir
|